Molecular approaches to epidemiology and clinical aspects of malaria

Parasitology Today

Volumn 16, Issue 10, 2000, Pages 448-451

  Brown, G V ^d   Beck, H P ^a   Molyneux, M ^b   Marsh, K ^c  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF MALAWI   (Malawi)

^c Ctr for Geogr Medicine Research   (Kenya)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; IMMUNITY; INFECTION CONTROL; MALARIA; MOLECULAR BIOLOGY; NONHUMAN; REVIEW; TECHNIQUE;

ANIMALS; CHILD; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 0034307764     PISSN: 01694758     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-4758(00)01793-2     Document Type: Review

References (42)

1. Al-Yaman F.M.et al. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 90:1996;270-273.
2. Anstey N.M.et al. Nitric oxide in Tanzanian children with malaria. inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression J. Exp. Med. 184:1996;557-567.
3. Burgner D.et al. Inducible nitric oxide synthase polymorphism and fatal cerebral malaria. Lancet. 352:1998;1193-1194.
4. Anstey N.M.et al. Nitric oxide, malaria, and anemia. inverse relationship between nitric oxide production and hemoglobin concentration in asymptomatic, malaria-exposed children Am. J. Trop. Med. Hyg. 61:1999;249-252.
5. Levesque M.C.et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J. Infect. Dis. 180:1999;1994-2002.
6. Kwiatkowski D.et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 336:1990;1201-1204.
7. Kwiatkowski D.et al. Anti-TNF therapy inhibits fever in cerebral malaria. Q. J. Med. 86:1993;91-98.
8. Kwiatkowski D.et al. Cerebral malaria. Lancet. 337:1991;1281-1282.
9. Clark I.A., Rockett K.A. Nitric oxide and parasitic disease. Adv. Parasitol. 37:1996;1-56.
10. English M.et al. Lactic acidosis and oxygen debt in African children with severe anaemia. Q. J. Med. 90:1997;563-569.
11. English M.et al. Clinical overlap between malaria and severe pneumonia in hospitalized African children. Trans. R. Soc. Trop. Med. Hyg. 90:1996;658-662.
12. English M.et al. Acidosis in severe childhood malaria. Q. J. Mal. 90:1997;263-270.
13. Clark I.A.et al. Nitric oxide and cerebral malaria. Lancet. 341:1993;632-633.
14. Schofield L.et al. Glycosylphosphatidylinositol toxin of Plasmodium upregulates intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. J. Immunol. 156:1996;1886-1896.
15. Brown H.et al. Cytokine expression in the brain in human cerebral malaria. J. Infect. Dis. 180:1999;1742-1746.
16. Rogerson S.J.et al. Chondroitin sulfate A is a cell surface receptor for Plasmodium falciparum-infected erythrocytes. J. Exp. Med. 182:1995;15-20.
17. Fried M., Duffy P.E. Maternal malaria and parasite adhesion. J. Mol. Med. 76:1998;162-171.
18. Rogerson S.J., Brown G.V. Chondroitin sulfate A as an adherence receptor for Plasmodium falciparum-infected erythrocytes. Parasitol. Today. 13:1997;70-75.
19. Beeson J.G.et al. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria. Nat. Med. 6:2000;86-90.
20. Biggs B.A.et al. Antigenic variation in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A. 88:1991;9171-9174.
21. Marsh K., Howard R.J. Antigens induced on erythrocytes by P. falciparum: expression of diverse and conserved determinants. Science. 231:1986;150-153.
22. Bull P.C.et al. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Med. 4:1998;358-360.
23. Cooke B.M.et al. Rolling and stationary cytoadhesion of red blood cells parasitized by Plasmodium falciparum. separate roles for ICAM-1, CD36 and thrombospondin Br. J. Haematol. 87:1994;162-170.
24. Cooke B.M.et al. Adhesion of malaria-infected red blood cells to chondroitin sulfate A under flow conditions. Blood. 88:1996;4040-4044.
25. Blackman M.J.et al. Processing of the Plasmodium falciparum major merozoite surface protein 1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol. Biochem. Parasitol. 49:1991;35-44.
26. Holder A.A.et al. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia. 41:1999;409-414.
27. Genton B.et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine. 18:2000;2504-2511.
28. Egan A.F.et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19 kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J. Infect. Dis. 173:1996;765-769.
29. Egan A.F.et al. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol. 21:1999;133-139.
30. Taylor R.R.et al. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2). increasing prevalence with age and association with clinical immunity to malaria Am. J. Trop. Med. Hyg. 58:1998;406-413.
31. Al-Yaman F.et al. Reduced risk of clinical malaria in children infected with multiple clones of Plasmodium falciparum in a highly endemic area. a prospective community study Trans. R. Soc. Trop. Med. Hyg. 91:1997;602-605.
32. Beck H.P.et al. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66. J. Infect. Dis. 175:1997;921-926.
33. Cheng Q.et al. Measurement of Plasmodium falciparum growth rates in vivo: A test of malaria vaccines. Am. J. Trop. Med. Hyg. 57:1997;495-500.
34. Figtree M.et al. Plasmodium vivax synonymous substitution frequencies, evolution and population structure deduced from diversity in AMA1 and MSP1 genes. Mol. Biochem. Parasitol. 108:2000;53-66.
35. Paul R.E.et al. Genetic analysis of Plasmodium falciparum infections on the north-western border of Thailand. Trans. R. Soc. Trop. Med. Hyg. 93:1999;587-593.
36. Bruce M.C.et al. Cross-species interactions between malaria parasites in humans. Science. 287:2000;845-848.
37. Miller L.H.et al. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, Fy/Fy. New Engl. J. Med. 295:1976;302-304.
38. Kidson C.et al. Ovalocytic erythrocytes from Melanesians are resistant to invasion by malaria parasites in culture. Proc. Natl. Acad. Sci. U. S. A. 78:1981;5829-5832.
39. Genton B.et al. Ovalocytosis and cerebral malaria. Lancet. 378:1995;564-565.
40. Hill A.V.S.et al. Common West African HLA antigens are associated with protection from severe malaria. Nature. 352:1991;595-600.
41. Kun J-F.et al. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet. 351:1998;265-266.
42. O'Donnell R.A.et al. Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nat. Med. 6:2000;91-95.